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T cells are involved in the pathogenesis of rheumatoid arthritis (RA). CD6 is a co-stimulatory molecule,
predominantly expressed on lymphocytes, that has been linked to autoreactive responses. The purpose of
this study was to evaluate the safety, immunogenicity and preliminary efﬁcacy of itolizumab, a humanized
anti-CD6monoclonal antibody, in patients with active rheumatoid arthritis. Fifteen patients were enrolled in
a phase I, open-label, dose-ﬁnding study. Five cohorts of patients received a weekly antibody monotherapy
with a dose-range from 0.1 to 0.8mg/kg. Itolizumab showed a good safety proﬁle, with no severe or serious
adverse events reported so far. No signs or symptoms associated with immunosuppression were observed in
the study.Objective clinical responseswere achieved inmore than80%ofpatients after treatment completion,
and these responses tend to be sustained afterwards. This clinical study constitutes the ﬁrst evidence of the
safety and positive clinical effect of a monotherapy using an anti-CD6 antibody in patients with rheumatoid
arthritis.
c© 2012 Elsevier B.V.
1. Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune dis-
ease characterized by symmetric inﬂammation of synovial joints,
leading to progressive erosion of cartilage and bone, restricted mo-
bility, and reduced life expectancy [1,2].
The currently available disease-modifying anti-rheumatic drugs
(DMARDs) used in conventional ﬁrst-line therapy provide some ben-
eﬁt, but generally fail to control the disease in a signiﬁcant number
of patients and furthermore, their clinical effects are often limited by
toxicity [3]. New andmore effective DMARDs continue to emerge and
in particular, biological agents that aim to inhibit cytokine activity,
block T cell-mediated co-stimulation, or modify B cell biology [4,5].
In spite of some encouraging therapeutic results, it should be noted
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that none of the biological therapies tested in clinical trials has been
able to induce ACR50 (approximately a 50% disease improvement) in
at least half of the patients. In fact, the best drugs provide only 10–
40% ACR70 [6]. In order to achieve additional signiﬁcant gains in RA
therapy, new therapeutic approaches need to be assayed.
The central role of T cells in the pathogenic immune response
in RA has been described elsewhere [7]. T lymphocytes contribute
to the initiation and perpetuation of RA immunopathology, lead-
ing to inﬂammation and, ultimately, joint destruction [8,9]. Acti-
vated T cells proliferate and recruit other immune cells such as
monocytes, macrophages, and synovial ﬁbroblasts, inducing them to
produce proinﬂammatory cytokines (tumor necrosis factor-α, TNFα;
interleukin-1, IL-1; interleukin-6, IL-6), prostaglandins, leukotrienes
and oxygen free radicals [8,10], and to stimulate osteoclastogen-
esis and matrix metalloproteinase secretion [11]. One of the co-
stimulatory pathways engaged in T cell activation involves the in-
teraction between the activated leucocyte-cell adhesion molecule
(ALCAM/CD166), found on antigen presenting cells, with the CD6
receptor on T cells [12,13].
CD6 is a highly glycosylatedmembrane protein predominantly ex-
pressed on lymphocytes. Its extracellular region is composed of three
scavenger receptor cystein-rich (SRCR) domains [14]. The third,mem-
brane proximal domain (SRCR3) contains the binding site for ALCAM
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Fig. 1. Scatter of individual values for total white blood cells (WBC) (A) and absolute
lymphocyte count (ALC) (B) for individual subjects of overall study cohort (safety pop-
ulation) over time. LLN: lower limit of normal; ULN: upper limit of normal. The graph
also shows the normal laboratory reference ranges and the clinically signiﬁcant range
as per CTCAE v 3 Grade 1.
[15,16]. It has been argued that CD6 may play a role in cell pro-
liferation, adhesion, differentiation and survival processes [17–19].
Recently, it was demonstrated that the CD6 co-stimulatory pathway
contributes to the Th1 activation and differentiation of human T cells,
promoting a preferentially proinﬂammatory response (TNFα, IL-6 and
interferon-γ) [20]. Under particular conditions, such activation pro-
cess may progress to an uncontrolled tissue inﬂammation, usually
characterized by an autoimmune immunopathology.
The relevance of CD6 in an autoimmune scenario has been previ-
ously discussed [21–25,28–30]. Initial studies demonstrated that CD6
negative T cells show less alloreactivity than their CD6 positive coun-
terparts, while anti-CD6monoclonal antibodies (mAbs) prevent renal
and bone marrow grafts rejection [26,27]. More recently, the ﬁnding
of CD6 as a susceptibility gene in multiple sclerosis, a prototypic au-
toimmune disease [28–30], supports the role of CD6 in pathological
autoimmunity leading to tissue inﬂammation and reinforces its rele-
vance for targeted therapy.
It is worth noting that the therapeutic effectiveness of anti-human
CD6 mAbs has been primarily associated with their ability to deplete
CD6 cells by a complement-mediated mechanism [27] or the capac-
ity of blocking the interaction between CD6 and its ligand ALCAM
[31,32]. However, several evidences suggest that signals delivered
upon stimulation of different epitopes of the CD6 molecule may pro-
duce different effects on T cells [21,33].
Itolizumab (T1h) is a humanized monoclonal antibody [34] that
recognizes the membrane-distal domain (SRCR1) of CD6 [35]. In
in vitro experiments using a soluble construction of the ALCAM
molecule, it was shown that T1h does not inhibit ALCAM binding to
T-cells. Furthermore, it was shown that T1h does not produce T-cell
depletion [35]. In spite of these properties, in vitro characterization
showed that itolizumab inhibits the T-cell proliferation induced in the
presence of ALCAM and excess IL-2, downregulates the phosphoryla-
tion of intracellular proteins implicated in the CD6-mediated activa-
tion pathways and reduces interferon-γ, IL-6 and TNF-α production
[20]. Hence, targeting CD6 in vivo with itolizumab would modulate
the immune response by reducing T-cell activation, proliferation and
pro-inﬂammatory responses.
It is remarkable that these inmunomodulatory effects are pro-
ducedwithout inhibiting ligand binding and inducing T cell depletion.
In this regards, it has been reported that there are antibodies which
instead of preventing ligand bindingmay cause receptor binding to be
non-productive. These interactions can result in either an inhibition
of new receptor formation, stimulation of the loss of existing recep-
tors, or a blockage followed by internalization or downregulation of
the receptors [36]. On the other hand, nondepleting mAbs have been
used to establish persistent T-cell tolerance [37]. All together, these
ﬁndings point to a potential newmechanism of action for itolizumab,
as compared with other anti-human CD6 mAb previously used in
clinical studies and other anti-CD6 antibodies assayed in preclinical
studies [21,22,38].
The parent antibody of itolizumab, the murine mAb ior T1, was
raised in BALB/c mice immunized with PBMCs from a patient with
Sezary’s syndrome [39,40]. Ior T1 mAb showed therapeutic effects in
autoimmune diseases, such as psoriasis and RA [23,24,41–43]. How-
ever, due to its murine origin this antibody needed to be humanized
aiming to eliminatemost of the undesired properties of murinemAbs
[34]. In this regard, the clinical use of humanized mAbs has revealed
a striking absence of adverse reactions. Based on these evidences, to-
gether with our previous ﬁnding that itolizumab exhibits the same
CD6 recognition proﬁle and a similar afﬁnity constant, but was less
immunogenic in monkeys than its murine or chimeric counterpart
[34,35], we expected itolizumab be less immunogenic and toxic than
its predecessors, leading to additional beneﬁts in RA patients.
The aim of the current study was to investigate the effect of a 6-
week monotherapy with itolizumab in biologic-naı¨ve patients with
active moderate to severe RA despite the previous DMARD therapy.
The primary intention of the study was to evaluate the safety and tol-
erability of different doses of itolizumab during 24weeks. In addition,
the study explores preliminary evidences of efﬁcacy.
2. Methods
2.1. Study design and endpoints
The study was an open-label, non-controlled, dose-ﬁnding phase
I trial, registered under number RPCEC00000007 at the Cuban Reg-
istry of Clinical Trials (www.registroclinico.sld.cu), and conducted at
a single clinical center in Havana, Cuba. For trial recruitment active
RA patients underwent an eligibility screening between July 2004 and
October 2006.
After awashout period (at least 4weeks forDMARDs andglucocor-
ticoids, and 2 weeks for NSAIDs), patients were sequentially enrolled
into cohorts of three patients, each receiving a different itolizumab
dose (0.2, 04 or 0.8mg/kg/day), once aweek during 6weeks. The dose
range was selected based on in vitro experiments and from the pre-
ceding experiences on clinical trials were performedwith themurine
ior T1 mAb on RA patients [23,24,41–43].
Twopatientswere assigned to 0.1 and0.6mg/kg, in two additional
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dose levels that were added during the course of the study. Subjects
were followed up for a period of 18 weeks after the last antibody ad-
ministration. The 24-weeks study period was divided into 2 stages:
week 0–6 was considered the treatment period while fromweek 7 to
week 24 was considered the post-treatment period (follow up). The
study medication was administered intravenously, once a week dur-
ing 6 weeks. The signs and symptoms were evaluated for 6 months,
starting from the ﬁrst dose administration. Clinical assessments were
performed at baseline and at weeks 7, 10 and 24, according to the
ACR core set of disease-activitymeasurements. Safetywasmonitored
during the whole study (weeks 0–24). The restriction for the use of
DMARDs, glucocorticoids andNSAIDswasextended fromthewashout
period, including the administration phase and up to 4 weeks after
the last itolizumab administration (follow-up, week 10), when these
drugs could be administered if disease ﬂares, according to the physi-
cian’s criteria. Otherwise, only analgesics were permitted. Patients
taking drugs for concomitant disease were required to have been on
chronic stable doses prior to screening. Such stable dose had to be
maintained throughout the study.
The primary endpoints were safety and tolerability of multiple
doses of itolizumab as administered by intravenous infusion. The
secondary endpoints were immunogenicity and prelimi-nary clini-
cal activity evaluation of the administered mAb. Since this study was
not designed for efﬁcacy assessment a blinded parallel group using
placebo was not included.
2.2. Ethics statement
This trial was conducted in full conformity with the principles
expressed in the Declaration of Helsinki. The protocol and related
documents were reviewed and approved by the institutional review
board from the participating institution and approved by the Cuban
National Regulatory Agency (State Center for Drug Quality Control).
All patients were recruited within the National Service for Rheuma-
tology in Havana and were given oral and written information about
the trial. All patients provided written informed consent before any
trial-speciﬁc procedurewas performed. An institutional reviewboard
committee (IRB) safeguarded the rights, safety, and well-being of all
trial subjects.
2.3. Study population
Eligible patients were aged 18–70 years, fulﬁlled the revised ACR
criteria for RA [44], at least one year before the screening, and had
active disease despite treatmentwith at least one DMARD. Active dis-
easewas deﬁned by the presence of at least four swollen and four ten-
der joints. Patients receiving a previous treatment with any DMARD,
glucocorticoids or nonsteroidal anti-inﬂammatory drugs (NSAIDs)
were eligible for participation after an appropriate washout period
before enrolment. Laboratory values within normal reference range
were required.
Patients were ineligible if they had history of, or current inﬂam-
matory joint disease, other than RA or other systemic autoimmune
disorder or any overlap syndrome. All pa-tients had to be using a
medically accepted form of contracep-tion at the time of enrolment
and had to continue its use through the follow up period.
2.4. Immunogenicity evaluation
The study was primarily focused on the anti-idiotypic response
after a prolonged exposure to the biological agent, when the IgG re-
sponse is predominant. The IgG anti-idiotypic response against the
variable region of the humanized itolizumab [34] was monitored
weekly during 10weeks after the ﬁrst administration. Ninety-sixwell
COSTAR
®
enzyme-linked immu-nosorbent assay plates (Corning In-
corporated, Corning, NY, USA) were coated with ior T1 (the murine,
parent antibody of itolizumab), at 5μg/ml phosphate buffered saline
(PBS) and incubated overnight at 2–8 ◦C. The plates were washed
with PBS containing 0.05% Tween 20 and blocked for 1h at 37 ◦C
with PBS containing 1% Bovine Serum Albumine (BSA). The plates
were then washed again and 1:400 and 1:800 serial dilutions of test
sera or positive control sera were added to the appropriate wells,
followed by incubation for 1h at 37 ◦C. A pool of sera from three
Monkeys (Cercopithecus aethiops) immunized with a chimeric prede-
cessor of T1h [34], having a known high reactivity in the assay, was
used as control. The pool showed an average optical density (405nm)
of 2,148. Plateswerewashed and an alkaline phosphatase-conjugated
goat anti–human IgG (Jackson Immunoresearch Laboratories, West
Grove, USA) antibody was added. Following 1h incubation at 37 ◦C,
plates were washed again and 1mg/ml paranitro-phenyl phosphate
in diethanolamine buffer was added to each well. After 30min at
25 ◦C in dark place, the reactions were stopped with 3N NaOH, and
the absorbance (405nm) was recorded. A post-treatment OD/pre-
treatment OD ratio = 2 was deﬁned as cutoff value for positive re-
sponses.
2.5. Statistical analysis
Safety was evaluated in the population who received at least one
dose of itolizumab,while clinical effectwas evaluated in the evaluable
population deﬁned as patients who received at least six doses of the
mAb. Patientswho did not achieve an ACR20were considered as non-
responders. Patients who dropped out the study or did not attend
physician evaluation at the time point to assess clinical effect were
considered as not available.
The incidence of adverse events and the proportion of patients
with a clinical beneﬁt expressed in a 20% improvement of signs and
symptoms (ACR20) or superior (ACR50 and ACR 70) were reported as
counts and percentages.
The ACR core data set consists of seven components: swollen joint
count (66 joints), tender joint count (68 joints), subject global as-
sessment of pain (VAS 100mm), subject global assessment of disease
activity (VAS 100mm), physician global assessment of disease activ-
ity (AS 100mm), and subject assessment of physical function using
HAQ and eritrosedimentation rate (ESR).
3. Results
3.1. Characteristics of the study population
A total of 15 patients were enrolled in the study. Three patients
were included into the three dose levels groups previously deﬁned
(0.2mg/kg, 0.4mg/kg and 0.8mg/kg). Two patients were addition-
ally included in the 0.4mg/kg group since two patients dropped-out
the study before the clinical assessment was completed (week 7). A
protocol amendment to include a 0.1 and 0.6mg/kg dose cohorts was
made after initiation of the trial, with two patients accrued in each
one (Table 1).
Data on patient disposition, demographics and other characteris-
tics at baseline are summarized in Tables 1 and 2. The patients were
predominantly women (73%) with moderate disease activity (80%)
and a median duration of the disease of 10 years across the ﬁve dose
groups. Patients showed active disease at recruiting despite previous
DMARD therapy, evidenced by more than four swollen and tender
joints at baseline (data not shown). All patients had received two or
more DMARDs before enrolment (Table 1). Since the washout period
accounted for a high baseline disease activity, the clinical status im-
mediately before the ﬁrst itolizumab dosewas considered as baseline
(W0) (Table 3A).
Fourteen patients, out of 15 that participated in the study, re-
ceived the scheduled six-infusions of itolizumab. Thirteen patients
reached the ﬁrst assessment point of the follow-up period (week 7);
while nine patients completed all the scheduled follow-up visits. A
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Fig. 2. Anti-idiotypic IgG response during T1h mAb therapy. The immunogenicity of the humanized T1h mAb was monitored prior to dosing and weekly until the week 10 after
ﬁrst administration. The IgG anti-idiotypic response of treated patients against the mouse variable region of the humanized mAb T1h was evaluated using an ELISA system coated
with the anti- CD6 mAb iort1. Positive response was considered when the ratio post-treatment OD/ pre- treatment OD was >2 for each patient.
Table 1.
Demographic indicators and disease characteristics at screening of the RA patients in the intent-to-treat population enrolled in the trial, by treatment group. Data are number of
patients (%) for categorical data and median (range) for continuous data. SJC = swollen joint count; TJC = tender joint count; DMARDs = disease-modifying antirheumatic drugs;
NSAIDs= nonsteroidal antiinﬂammatory drugs; RF= rheumatoid factor; CRP= C-reactive protein; ESR= erythrocyte sedimentation rate; HAQ=Health Assessment Questionnaire.
Characteristics T1h mAb dose levels Combined T1h groups
0.1mg/kg (n = 2) 0.2mg/kg (n = 3) 0.4mg/kg (n = 5) 0.6mg/kg (n = 2) 0.8mg/kg (n = 3) Total (n = 15)
Female, no. (%) 2 (100) 1 (33.3) 4 (80) 2 (100) 2 (66.6) 11 (73.3)
Age (years) 41.5 (31–52) 42 (41–49) 60 (41–62) 40 52 (39–61) 52 (31–69)
Weight (kg) 83 (82–84) 75 (63–90) 75 (51–96) 67.5 (65–70) 73 (65–82) 73 (47–96)
Disease duration
(years)
6.5 (1–12) 18 (12–20) 3 (2–20) 11 (2–20) 6 (2–27) 10 (1–27)
Disease activity, no. (%)
Moderate 0 3(100) 5 (100) 2 (100) 2 (66.7) 12 (80)
Severe 2 (100) 0 0 0 1 (33.3) 3 (20)
Prior medications, no. (%)
Methotrexate 2 (100) 2 (66.6) 3 (60) 2 (100) 2 (66.6) 11 (73.3)
Other DMARDs 2 (100) 3 (100) 1 (20) 2 (100) 3 (100) 11(73.3)
Corticosteroids 1 (50) 3 (100) 5 (100) 1 (50) 3 (100) 13 (86.6)
NSAIDs 2 (100) 3 (100) 5 (100) 2 (100) 3 (100) 15 (100)
RF positive 1 (50) 2 (66.7) 4 (80) 1 (50) 2 (66.7) 10 (66.6)
CRP positive 2 (100) 2 (66.7) 4 (80) 2 (100) 3 (100) 14 (93.3)
total of six patients (40%) did not complete the study. Two (33.3%)
out of six patients discontinued during the treatment period after
using a restricted concomitant medication, one of them to treat or-
dinary symptoms of dyspepsia and the second one as rescue therapy
because of lack of effectiveness. Three patients (50%) were discontin-
ued because of loss of follow-up. One patient (16.6%) discontinued
voluntarily (Table 2).
3.2. Primary endpoint
Safety analysis was based on all subjects who received at least one
dose of itolizumab, which represented 100% of patients. None of the
patients discontinued because of safety reasons.
No treatment-related serious adverse events (SAE) or severe in-
fections were reported. All subjects experienced at least one adverse
event during the 24-week study, but there was no evidence of a re-
lationship between the dose and the intensity, duration or frequency
of these adverse events. The majority of them were of mild (63.3%)
or moderate (36.3%) severity. One subject from the 0.4mg/kg dose
group experienced a severe adverse event (a headache) which was
classiﬁed as not related to the study drug. No AEs resulted in either
discontinuation or reduction of the dose of the study drug.
From the 225 AEs reported during overall study, 178 events (79%)
were considered to be related to the study agent by the investigators.
From these 178 EAs, 128 (72%) occurred during the treatment period
while 50 (28%) took place during the follow-upperiod. Themajority of
them (77AEs, 43%) were suggestive of peri-infusional events (deﬁned
as adverse events occurring within the 24h following the infusion)
with a considerable decline in frequency observed after 3 weeks of
treatment. The most commonly reported AEs included headache (27
AEs, 15%), fever (22 AEs, 12%) and chills (14 AEs, 7%). Only 43 AEs
(24%) were considered to be likely or very likely related to the study
agent.
Taking into account that CD6 is a lymphocyte marker that plays
an important role in immune function, we determined whether
itolizumab treatment has an effect on the white blood cells count
(WBC) and in particular, the lymphocyte population (ALC) for all the
15 RA patients enrolled in the trial. Four patients showed laboratory
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Table 2.
Most frequently reported adverse events (n = 15). All adverse events affecting more
than 10% of patients in any one group are shown. Values are the number (%).
Number (%) n = 15
Adverse events
Death 0
Serious adverse events 0
Serious infections 0
Any adverse event 15 (100)
Most frequently adverse events
Headache 11 (73)
Fever 9 (60)
Chills 9 (60)
Nausea 7 (46)
Anorexia 7 (46)
Asthenia 7 (46)
Local erythema 6 (40)
Pruritus 6 (40)
Vomiting 3 (20)
Diarrhea 2 (13)
Discontinuations (reasons) 6 (40)
Adverse event 0
Withdrawal of consent 1 (16)
Lost to follow-up 3 (50)
Use of restricted drugs 2 (33)
Death 0
values out of the normal reference ranges for WBC counts; two of
them were under the lower limit (from the 0.4mg/kg and 0.6mg/kg
groups), while the other two were over the upper limit (0.1mg/kg
and 0.4mg/kg groups). In one of them (0.4mg/kg group) the tran-
sient increase of WBC was associated with an increase in neutrophils
and a severe RA. It has been reported that WBC elevation is primarily
caused by the increase in neutrophils, and that those patients tend to
havemore active arthritis [45]. In three other patients these AEs came
out before starting the treatment. All these AEs were graded as mild
in intensity and were deemed not related to the study medication.
In general, WBC and absolute lymphocyte counts were stable across
the entire study, regardless of the dose levels. No abnormalities were
observed in patients from the highest dose group (0.8mg/kg) (Fig. 1
A and B).
The other hematological abnormalities frequently detected in the
study were mild thrombocytosis and anemia. Such kinds of hemato-
logic disorders are common in patients who suffer an active RA [46],
therefore, these AEs were considered as primary disease progression
or recurrence and not related to the study medication. Moreover, the
hemoglobin values tended to increase throughout the study.
Three out of six patientswith urinary symptoms (dysuria, polyuria
and nicturia) were diagnosed of urinary tract infection (UTI) but only
for one patient (arm 0.4mg/kg) the symptom was considered as
‘related’ to the study drug. The other two patients (0.4mg/kg arm
and 0.6mg/kg arm) showed low WBC counts before the study, and
one of them had, in addition a history of type 2 Diabetes mellitus
and recurrence of UTI. All patients with UTI were treated with oral
antibiotics and recovered completely before the end of study.
Since concurrent treatment with any DMARDs, glucocorticoids or
NSAIDs was allowed after week 10; four patients were consequently
medicatedbecauseof diseaseﬂares. Threepatients received lowdoses
of oral corticosteroid and one patient used low doses of DMARD.
3.3. Secondary endpoints
3.3.1. Anti-idiotypic IgG antibody response
None of the serum samples from the 15 patients across the dif-
ferent dosage cohorts developed signiﬁcant immunogenic responses
after completion of week 10. The low measurable anti-idiotype an-
tibody response was transient and independent of the amount of
administered protein (Fig. 2). There were no evidences of any rela-
tionship between the anti-idiotype antibody response and the dose
or clinical efﬁcacy.
3.3.2. Efﬁcacy evaluation
The clinical efﬁcacy outcomes, assessed by the improvements in
at least seven individual components of the ACR score and the rate of
ACR 20, ACR 50 and ACR 70, were performed at weeks 7, 10 and 24
from the beginning of the study. The clinical assessment immediately
before the ﬁrst itolizumab dose was considered as baseline (W0).
Taking advantage of the small number of patients included in the
study and taking into account the safety aimof the study apreliminary
efﬁcacy analysis was performed by a full set analysis.
Already by the ﬁrst assessment point of the follow-up period
(week 7), the overall study cohort analysis showed improvements
from baseline values in all ACR criteria components (Table 3A, W7).
Most of the variables showed over 50% improvements. These results
correlate with the high proportion of subjects achieving an ACR20
response rate (84%). The proportion of ACR50 and ACR70 responders
was 76% and 23%, respectively (Table 3B, W7). At the subsequent as-
sessment point (week 10, 4 weeks after the last itolizumab dose) the
improvements tended to persist (Table 3 A and B, W10).
By week 24, there were signiﬁcant improvements in all variables
as compared with baseline (W0) and week 7. However, since the
restriction for the use of DMARDs had previously already concluded,
the clinical impact at this assessment point is limited. The analysis
included three patients who received low-dose oral glucocorticoids
but excluded one patient who was medicated with a DMARD (Table
3 A and B, W24).
Although six patients were missing at several assessment points,
most of them dropped out during the follow-up (66.6%) and mostly
after week 20 (50%). These patients showed ACR response in the last
recorded visit (one ACR 50, two ACR 70 and one ACR 20).
Apredominant effectwas seen in someparticularRAclinicalmark-
ers such as SJC, PAP, HAQ and ESR. In these variables a trend toward
the increase of improvement was sustained across the entire follow-
up (Table 3A).
The clinical effect was also notable for hemoglobin values. The
trend to decrease observed during thewashout periodwas associated
with RA exacerbation as a consequence of the restriction for the use
of DMARDs. Once the treatment started a stabilization was observed
and turned into increase until the end of treatment phase. The highest
values were reached at week 24 (Fig. 3).
Among those who received different doses there were no differ-
ences between the proportions of patients who achieved ACR20 or
higher clinical response, considering the small number of subjects in
each group.
4. Discussion
Despite the evident success of several new biological therapies,
concerns remain regarding their immunosuppressive effects and the
associated increased risk of infection [47]. Therefore, the need for
further advances and alternative therapies is clear.
A few agents are targeted to inhibit T-cell activation rather than
block the consequences of activation—as most of current biological
DMARDs do [48]. Evidences of clinical beneﬁts of blocking T cell sig-
nalling in RA patients have been conﬁrmed [49,50]. In this regard,
anti-CD6 therapy is an emerging ﬁeld to improve clinical beneﬁt in
activeRA,withprevious experiences obtained fromstudiesdeveloped
in graft rejection and autoimmunity [51–54]. Such therapeutic inter-
vention should modulate T lymphocyte activation, auto-recognition
and trafﬁc through the joints.
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Table 3.
Efﬁcacy of T1h at weeks 7, 10 and 24, by combined T1h groups. (A) Median (range) of ACR components. Median of percentage of improvement in ACR components (changes in the
individual patient data frombaseline (W0) toW7,W10 andW24): 100 × baseline value – day × value]/baseline value. SJC= swollen joint count; TJC= tender joint count; DMARDs
= disease-modifying antirheumatic drugs; NSAIDs = nonsteroidal antiinﬂammatory drugs; RF = rheumatoid factor; CRP = C-reactive protein; ESR = erythrocyte sedimentation
rate; HAQ = Health Assessment Questionnaire; PAP = Patient Assessment of Pain; Global Disease Assessment by Patient = GDAP; Global Disease Assessment by Observer = GDAO.
(B) Proportion of patients with improvement in ACR criteria (ACR20, ACR50, ACR70).
RA assessment Median (range) Median (range)
Median change
from baseline
(range) Median (range)
Median change
from baseline
(range) Median (range)
Median change from
baseline (range)
W0, n = 13 W7, n = 13 W10, n = 12 W24a, n = 8
A
SJC 21.0 (4.0–37.0) 2.0 (0.0–23.0) 81.0 3.5 (0.0–24.0) 76.3 1.0 (0.0–9.0) 95.0
TJC 26.0 (5.0–49.0) 7.0 (2.0–24.0) 60.0 5.0 (2.0–22.0) 67.5 2.0 (0.0–11.0) 85.0
PAP 8.0 (5.0–10.0) 4.0 (0.5–10.0) 50.0 2.5 (1.0 -8.0) 65.0 1.0 (0.0–8.0) 87.5
GDAP 8.0 (3.0–10.0) 3.0 (0.5–10.0) 66.7 3.0 (1.0–7.0) 62.8 1.0 (0.0–7.0) 81.9
GDAO 8.0 (4.0–10.0) 3.0 (0.0- 7.0) 66.7 3.0 (0.5–9.0) 62.8 1.0 (1.0- 6.0) 88.2
HAQ- DI 1.3 (0.3–3.0) 0.8 (0.0–2.0-) 55.4 0.6 (0.0 – 1.7) 60.5 0.1 (0.0–1.0) 97.3
ESR 42.0 (10.0–103.0) 40.0 (2.0–90.0) 22.1 35.0 (2.0- 94.0) 30.9 25.0 (7.0- 71.0) 44.9
B
ACR responses Combined T1h groups
W7, n = 13b W10, n = 12c W24, n = 8d
ACR ≥ 20 11 (84.6%) 11 (91.6) 8 (100%)
ACR ≥ 50 10 (76.9%) 8 (66.6%) 8 (100%)
ACR ≥ 70 3 (23.0%) 3 (25%) 2 (25%)
a One patient was excluded for the analysis because received DMARD.
b Two patients abandoned before ﬁrst clinical assessment.
c One patient voluntary withdrawn.
d Two patients were lost to follow-up, one patient did not attend physician evaluation and one was additionally excluded for the analysis because received DMARD.
Fig. 3. Change in hemoglobin with T1h treatment during the study. LLN: lower limit
of normal.
Itolizumab (T1h) is an anti-CD6monoclonal antibodywith clinical
potential in the treatment of RA. A series of in vitro tests demonstrated
that itolizumab inhibits CD6 mediated co-stimulation, reducing lym-
phocyte proliferation and pro-inﬂammatory cytokine production.
The study presented here was an exploratory, phase I, open la-
bel, dose range-ﬁnding trial involving biologically naı¨ve patientswith
active RA. The primary endpoint of the study was to demonstrate
and characterize the incidence of adverse events’ rates of itolizumab
monotherapy through dose escalation. Up to 6 weekly administra-
tions of itolizumab at different doses (ranging from 0.1 to 0.8mg/kg)
were well tolerated and safe without any discontinuation because of
safety reasons.
Immunogenicity is the main limitation for the use of mAbs. The
treatmentmay result in the generation of antibodies against the ther-
apeutic agent that, which interferewith the therapy. In particular, the
generated antibodies may reduce the mAb half-life as consequence
of increased clearance and produce undesired side effects which may
limit theuseof thedrug. Asweexpected, basedonaprevious evidence
of very low immunogenicity of itolizumab inmonkeys, the study drug
did not show signiﬁcant immunogenicity in patients. There were no
evidences of relationship between the low measurable anti-idiotype
antibody response and the dose or clinical efﬁcacy. The lack of anti-
idiotypic responseobserved inRApatients correlatedwitha reduction
in the type and intensity of AEs. Following an initial high incidence of
mostly mild to moderate infusion-related AEs during the ﬁrst week
of treatment, itolizumab was well-tolerated.
Itolizumabmonotherapy did notmodify signiﬁcantly the lympho-
cyte population during the course of the study. Likewise, there were
not documented signs or symptoms which could be interpreted as
immunosuppression induced by themAb at any dose level during the
therapy. These results suggest a different mechanism of action for
itolizumab, not mediated by immune depletion, and provide a plau-
sible explanation for the safety proﬁle observed even at the highest
dose level.
On the other hand, in previous clinical trials using ior T1, the mAb
was administered intravenously once daily during 7 days, since the
median half life time of this murine mAb was in the range 13.93–
19.67h [24,55]. In these studiesmostpatients showedclinical beneﬁts
approximately up to 4 months after the ﬁrst infusion. In our study,
itolizumab was administered once weekly for 6 weeks and clinical
beneﬁts were observed at least up to 6 months after ﬁrst infusion.
Although we have not pharmacokinetics data at the time of this re-
port, we hypothesize that the lack of anti-idiotypic response beneﬁts
the long term efﬁcacy of itolizumab and permits a more comfortable
schedule of administration.
The secondary endpoint evaluated preliminary evidences of ther-
apeutic effect of itolizumab therapy in subjects without concomi-
tant background DMARD therapy. In this scenario, itolizumab used
as monotherapy achieved improvements in disease-related clinical
markers. In the full set analysis, an objective clinical response was
seen in most of the patients with ACR20, one week after the last dose
administration. Itolizumab also showed effect at ACR50 and ACR70,
which aremore stringentmeasures of patient responses to treatment.
Signiﬁcantly, the clinical response had a tendency to persist 4
weeks after the last itolizumab administration. Moreover, it is of note
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that although the restriction for the use of DMARDs during the study
was foreseen to extend just up to 4weeks after the last itolizumab ad-
ministration,most of thepatients (53.3%) didnot receive anyDMARDs
within the next 18 weeks from the last itolizumab dose (week 24)
and nonetheless ACR 50 and ACR 70 were achieved. This sustained
improvement along the follow-up period suggests that the treatment
acts not only on the signs and symptoms, but also on the etiopathol-
ogy of the disease. Moreover, it is important tomention that although
therewas a relatively high patientwithdrawal rate (40%) in the study,
the patients that abandoned the study did it in spite of the clinical
beneﬁts.
In patients with RA, anemia is the most common hematologic ab-
normality (prevalence ranges from 30% to 70%), which correlate with
disease activity [56–59]. In our study we observed that itolizumab
treatment leads to an increase in hemoglobin levels, which suggests a
control of the disease despite no speciﬁc anti-rheumatic therapy but
itolizumab monotherapy. The safe proﬁle together with preliminary
evidence of a sustainable efﬁcacy response suggests that itolizumab
is suitable for long-term treatment regimens.
Our study, nonetheless, has several limitations. This was the ﬁrst-
in-human dose escalation study conducted using itolizumab to deﬁne
a safety dose range,which required an open-label design. This context
and the consequent absence of a placebo-control arm limit our inter-
pretation of efﬁcacy. Moreover, the small sample size together with
the relatively high number of non-compliances occurred in the trial
reduces the power of the study, makes it difﬁcult to deﬁne an optimal
biological dose for treatment and to conduct a PK study, and leads
to an underestimation of the safety and efﬁcacy of the treatment. Fi-
nally, the 6-week treatment periodwas short. Since, proof-of-concept
trials in RA require at least 3 months of treatment to allow sufﬁcient
time for improvements of the active disease to be demonstrated and
to conﬁrm that the beneﬁt continues. This requirement has several
important implications including the necessity for toxicology studies
of sufﬁcient duration to cover 12 weeks of dosing of a new agent in
the clinic [60]. Third, the 24-week monitoring period is not enough
for a long-term assessment to fully characterize the safety proﬁle of
itolizumab.
Nevertheless, this 6-week, ascending-dose trial involving 15 pa-
tientswhohad activemoderate to severe rheumatoid arthritis despite
non-biologic DMARD therapy, offers the ﬁrst preliminary evidences
of safety and clinical beneﬁt using itolizumab monotherapy in RA
patients. Our results point to a new potential mechanism for RA ther-
apy, not mediated by immunosuppression, to achieve long lasting
clinical beneﬁts through T-cell response modulation. Although this
study was not able to deﬁne a therapeutic dose based on efﬁcacy re-
sults, it could be considered as the ﬁrst valuable clinical application
of mAb itolizumab. The encouraged safety proﬁle shown by the an-
tibody in this study prompted us to desing a long lasting schedule of
monotherapy with itolizumab in larger cohorts of patient with active
RA.
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